Your browser doesn't support javascript.
loading
SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023).
López, Carlos López; Calvo, Mariona; Cámara, Juan Carlos; García-Paredes, Beatriz; Gómez-Martin, Carlos; López, Ana María; Pazo-Cid, Roberto; Sastre, Javier; Yaya, Ricardo; Feliu, Jaime.
Afiliação
  • López CL; Medical Oncology Department, H. U. Marqués de Valdecilla, IDIVAL, UNICAN, Santander, Cantabria, Spain. carlos.lopez@scsalud.es.
  • Calvo M; Medical Oncology Department, Institut Català d'Oncologia-L'Hospitalet del Llobregat, Barcelona, Spain.
  • Cámara JC; Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
  • García-Paredes B; Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain.
  • Gómez-Martin C; Medical Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
  • López AM; Medical Oncology Department, Hospital Universitario de Burgos, Burgos, Spain.
  • Pazo-Cid R; Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Sastre J; Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain.
  • Yaya R; Medical Oncology Department, Instituvo Valenciano de Oncología, Valencia, Spain.
  • Feliu J; Medical Oncology Department, Hospital Universitario de La Paz, IdiPAZ, CIBERONC, UAM, Madrid, Spain.
Clin Transl Oncol ; 2024 Jun 24.
Article em En | MEDLINE | ID: mdl-38914756
ABSTRACT
Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver and is the third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be offered to individuals at high risk for developing HCC. Accurate diagnosis, staging, and liver function are crucial when determining the optimal therapeutic approach. The BCLC staging system is widely endorsed in Western countries. Managing this pathology requires a multidisciplinary, personalized approach, generally with a multimodal strategy. Surgery remains the only curative option, albeit local and systemic therapy may also increase survival when surgery is not suitable. In advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child-Pugh class A.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha